Rituximab Improves Paclitaxel/Topotecan Salvage Efficacy in NHL

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

ORLANDO-Adding rituximab (Rituxan) to paclitaxel (Taxol)/topotecan (Hycamtin) salvage therapy raises response rates by about 25%, more than triples complete response rates, and is effective in both primary refractory and relapsed aggressive B-cell lymphomas.

ORLANDO—Adding rituximab (Rituxan) to paclitaxel (Taxol)/topotecan (Hycamtin) salvage therapy raises response rates by about 25%, more than triples complete response rates, and is effective in both primary refractory and relapsed aggressive B-cell lymphomas.

Phase II Study

Anas Younes, MD, and colleagues from M. D. Anderson Cancer Center reported data from a 45-patient phase II study of the paclitaxel/topotecan/rituximab regimen in a poster presentation at the 43rd Annual Meeting of the American Society of Hematology (ASH abstract 1456).

"We concluded that rituximab improves the response rate of paclitaxel/topotecan and increases the proportion of complete remissions. There was not a significantly different toxicity profile with the addition of rituximab. However, this is not frontline treatment yet," Dr. Younes told ONI in an interview.

The study enrolled 45 patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma (NHL) and included 34 with diffuse large cell, 4 with follicular large cell, and 7 with transformed disease. Twenty patients (44%) had primary refractory disease, and 25 (56%) had relapsed after responding to previous therapy. Most patients had received only a single previous regimen, and 15 (33%) had received prior cytarabine/platinum. The median age was 58.

The regimen included paclitaxel 200 mg/m²IV given over 3 hours on day 1, topotecan 1 mg/m² IV given each day on days 1 to 5, and rituximab 375 mg/m² given 1 day before each paclitaxel/topotecan course. All patients also received prophylactic filgrastim (G-CSF, Neupogen). Courses were repeated every 3 weeks, and patients received a median of three courses.

In patients with primary refractory disease, adding rituximab to the regimen increased the response rate to 55% from the 31% Dr. Younes had reported in a previous study of paclitaxel/topotecan in a similar group of patients.

The quality of response also improved dramatically, with complete responses rising from 6% with paclitaxel/topotecan to 25% with the three-drug regimen.

The combination had similar effects in patients who had relapsed after initially responding to therapy. Adding rituximab increased the response rate to 80% from the 65% seen previously with paclitaxel/topotecan, and increased the complete response rate from 18% to 60%.

Toxicity

"Toxicity was comparable to what we had seen with paclitaxel/topotecan alone," Dr. Younes said. A total of 159 cycles of therapy were delivered. Neutrophil counts of less than 500/µL were observed after 66 cycles (42%), and platelets below 10,000/µL after 16 cycles (10%). There were no serious nonhematologic toxicities. Febrile neutropenia occurred in 7 of 45 patients (16%). 

Related Videos
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
A panel of 4 experts on multiple myeloma
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Related Content